ACE and chronic kidney disease: The mainstays of nonspecific secondary prevention of chronic kidney disease (CKD) progression, irrespective of cause, include blood pressure control and proteinuria-directed strategies to preserve residual kidney function, with special emphasis on angiotensin-converting enzyme inhibitors (ACEi) or angiotensin-receptor blockers (ARB) [1–4].